Sano Genetics/X
Jul 31, 2025, 15:37
Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab
Sano Genetics shared an inviting post on X:
”Tune in to Episode 198 of The Genetics Podcast.
This week, we’re joined by Benny Sorensen, CEO of Hemab Therapeutics. Tune in to hear about how Benny’s persistence and “unreasonable” leadership led to Hemab’s first program, how Hemab is reimagining clotting therapies by centering patient voices, and the value of their multi-modality and collaborative approach.”
Listen to the Apple Podcast here.
Listen to the YouTube Podcast here.
Stay tuned with Hemostasis Today.
-
Nov 14, 2026, 09:42Samwel Mikaye: What Every Patient Should Know About DVT Symptoms and Treatment
-
Nov 14, 2026, 09:37Chronic Preoperative Corticosteroid Use and Postoperative Venous Thromboembolism Risk – Thrombosis and Haemostasis Journal
-
Nov 14, 2026, 09:30Ney Carter Borges: Vulnerable Plaque – Imaging and Clinical Significance
-
Nov 14, 2026, 09:25Carmelo Raffo: How Much Antithrombotic Therapy is Truly Necessary after LAAC?
-
Nov 14, 2026, 09:19Mary Cushman: Excellent to Have Jordan Shavit Visit Us for a Virtual Lab Meeting Today
-
Nov 14, 2026, 09:15Chancellor Donald: Heading to ASH 2026 in New Orleans? Let’s Connect on Faculty Opportunities at Tulane
-
Nov 14, 2026, 09:11Sajja Venkatesh: FDA Approved Asundexian, the First Factor XIa Inhibitor
-
Nov 14, 2026, 09:05Selina Evans: How Can Hospitals Make VTE Risk Assessment and Prevention Truly Routine?
-
Nov 14, 2026, 09:01Abdul Rehman Abid: DAPT vs Aspirin Monotherapy Beyond 12 Months Following Drug-Eluting Stent Implantation